Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Editor’s Pick: Five Healthcare News Headlines for Jan. 12 - 25
January 26, 2015
- Japan-Version Compassionate Use May Cover Drugs with No Approval Globally
January 26, 2015
- Council OKs Application Based on Info in Public Domain for Taxol Once Weekly for 3 Weeks for Gastric Cancer
January 26, 2015
- PMDA Evaluating Apixaban for Risk of Interstitial Pneumonia
January 26, 2015
- Government Launches Genomic Medicine Panel
January 23, 2015
- Chuikyo’s HTA Panel to Hold Closed Meeting on Jan. 28
January 23, 2015
- NIBIO Chief Pins Hopes on Potential Synergies from Impending Merger
January 22, 2015
- NIBIO Completes Development of Prototype Adjuvant Database
January 22, 2015
- PAFSC’s Second Committee on Drugs Recommends Approval for Eisai’s Lenvatinib
January 22, 2015
- R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017
January 21, 2015
- Health Ministry Reveals Guidelines on Research Misconduct
January 20, 2015
- R&D Tax Credit Revamp (1): New Scheme for Open Innovation Research Significant in 3 Ways
January 20, 2015
- Consumer Affairs Agency to Begin Study on Child-Resistant PTP Sheets
January 20, 2015
- PAFSC 1st Committee to Discuss Takeda’s Once-Weekly DPP-4 Inhibitor on Jan. 30
January 20, 2015
- NIBIO to Launch Project to Collate Compound Libraries, Academic Seeds
January 19, 2015
- AMED Chief-to-Be Vows to Overhaul Siloed Research Grants
January 19, 2015
- PMDA Head Expresses Full Support for AMED
January 19, 2015
- 112.8 Billion Yen Allotted to Intractable Disease Measures
January 19, 2015
- 65 Institutions to Treat Post-HPV Vaccine Adverse Reactions
January 16, 2015
- MHLW to Reorganize Health Service Bureau in FY2015
January 16, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…